PDGF Receptor beta Antibody - #AF6133

Figure 2 Optimization of expression conditions: (A) investigation of added silica gel in per 50 μL system, (B) investigation of expression time: observe the amount of inserted and not-inserted PDGFRβ at 1 or 2 h expression time, (C) investigation of insertion time given to PDGFRβ, (D) investigation of maximum proportion of DOPE, (E) quantification analysis of bands in (C), (F) quantification analysis of bands in (D).

Figure 6. - TFRD promotes CD31hiEmcnhi vessel formation in angiogenic-osteogenic coupling during distraction osteogenesis via the PDGF-BB/PDGFR-β pathway. (A) Representative immunofluorescence images and (B) quantification of RUNX2, OSX, CD31 and PDGF-BB in the distracted tibias after distraction for 4 weeks. (C) Representative western blotting images and (D) semi-quantitative analyses of PDGF-BB, VEGF, RUNX2, OSX as well as the phosphorylation of AKT and ERK1/2 in the distracted tibias at 4 weeks post-distraction. (E) Quantification of mRNA expression levels of PDGF-BB, VEGF, RUNX2 and OSX. Data represent the mean ± SD. n=3 rats in each group from three independent experiments. *P

The precisely detection and dissection of pancreatic adenocarcinoma by the probes based on a novel PDGFRβ targeting peptide.

Fig. 4 The expression of PDGFD and PDGFRB in osteosarcoma. a UMAP plot displayed PDGFD highly expressed in the non-metastatic osteosarcoma. b UMAP plot displayed similar expression of PDGFRB in the non-metastatic and metastatic osteosarcoma. c Immunohistochemical staining for PDGFD and PDGFRB in samples and organoids. Black scale bars: 30 μm. d PDGFD positivity was significantly higher in non-metastatic osteosarcoma primary lesions than metastatic primary lesions. e The differing positive rate of PDGFRB between non-metastatic osteosarcoma primary lesions and metastatic primary lesions was not statistically significant. * p  0.05. f Multi-color immunofluorescence analysis revealed that PDGFD and PDGFRB were co-localized. Color code: Blue = DAPI, Red = COL1a1, Green = PDGFD, Yellow = PDGFRB. White scale bars: 40 μm.

Figure 5Adenovirus-mediated overexpression of corin ameliorates kidney fibrosis after unilateral ureteral obstruction (UUO). A: Experimental design. Green arrow indicates the time point of UUO and injection of corin-overexpressing adenovirus (Adeno-corin) or blank adenovirus (Adeno-blank). Fluorescence activity was detected 48 hours after UUO and adenovirus infection to confirm adenovirus gene delivery. B: Representative micrographs of kidney tissues in different groups at day 7 after UUO as indicated. Kidney sections were subjected to Sirius red and Masson trichrome staining. C: Graphic presentation showing the area of Masson trichrome and Sirius red staining in kidney tissues among the indicated groups. D: Representative immunohistochemical micrographs of α-smooth muscle actin (α-SMA) and fibronectin at day 7 after UUO. Paraffin-embedded kidney sections were stained with α-SMA and fibronectin antibodies. Arrows indicate positive staining. E and F: Western blot analysis of α-SMA, fibronectin, and collagen I in kidney tissues at day 7 after UUO. Representative gel images (E) and quantitative data (F) are shown. G and H: Immunohistochemical and immunofluorescence staining of platelet-derived growth factor receptor β (PDGFR-β) in kidney tissues of different groups as indicated at day 7 after UUO. PDGFR-β is a pericyte marker. Representative micrographs (G) and quantitative data (H) are presented. I and J: Immunohistochemical and immunofluorescence staining of CD31 in kidney tissues of different groups as indicated at day 7 after UUO. CD31 is the marker of mature endothelial cells. Representative micrographs (I) and quantitative data (J) are presented. Data are the means ± SEM (C, F, H, and J). n = 5 animals per group (C, F, H, and J). ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001. Scale bars = 50 μm (B, D, G, and I). GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

Figure 5Adenovirus-mediated overexpression of corin ameliorates kidney fibrosis after unilateral ureteral obstruction (UUO). A: Experimental design. Green arrow indicates the time point of UUO and injection of corin-overexpressing adenovirus (Adeno-corin) or blank adenovirus (Adeno-blank). Fluorescence activity was detected 48 hours after UUO and adenovirus infection to confirm adenovirus gene delivery. B: Representative micrographs of kidney tissues in different groups at day 7 after UUO as indicated. Kidney sections were subjected to Sirius red and Masson trichrome staining. C: Graphic presentation showing the area of Masson trichrome and Sirius red staining in kidney tissues among the indicated groups. D: Representative immunohistochemical micrographs of α-smooth muscle actin (α-SMA) and fibronectin at day 7 after UUO. Paraffin-embedded kidney sections were stained with α-SMA and fibronectin antibodies. Arrows indicate positive staining. E and F: Western blot analysis of α-SMA, fibronectin, and collagen I in kidney tissues at day 7 after UUO. Representative gel images (E) and quantitative data (F) are shown. G and H: Immunohistochemical and immunofluorescence staining of platelet-derived growth factor receptor β (PDGFR-β) in kidney tissues of different groups as indicated at day 7 after UUO. PDGFR-β is a pericyte marker. Representative micrographs (G) and quantitative data (H) are presented. I and J: Immunohistochemical and immunofluorescence staining of CD31 in kidney tissues of different groups as indicated at day 7 after UUO. CD31 is the marker of mature endothelial cells. Representative micrographs (I) and quantitative data (J) are presented. Data are the means ± SEM (C, F, H, and J). n = 5 animals per group (C, F, H, and J). ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001. Scale bars = 50 μm (B, D, G, and I). GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

Fig. 8. Detection of wound healing conditions by growth factor expression. Detection of the expression of wound healing-related growth factors in the wound tissue of the control, CS, HUC-MSC + CS, and HUC-MSC EXO + CS groups on days 3, 7, 10, 14, and 16 by western blot. *P